Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D

Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership. Dr. Chris Boshoff has been promoted to the role of Chief Oncology R&D Officer and Executive Vice-President (EVP), marking an internal shift as he previously managed clinical research for Pfizer’s oncology and rare disease portfolio.

Expansion of Dr. Dolsten’s Role
In a complementary move, Pfizer’s current Chief Scientific Officer and President of Pfizer Worldwide Research, Dr. Mikael Dolsten, has expanded his role to include leadership of all discovery, early- and late-stage clinical development for all non-oncology therapeutic areas. As the new Chief Scientific Officer and President of Pfizer Research & Development, Dolsten will oversee a broader range of the company’s scientific endeavors.

Departure of William Pao
The reshuffle also sees the departure of William Pao, who served as Chief Development Officer and EVP. Pao joined Pfizer 16 months ago after a previous tenure as head of pharma research and early development at Roche.

Reflecting Pfizer’s Strategic Direction
These changes within Pfizer’s R&D leadership reflect the company’s strategic focus following its massive USD 43 billion acquisition of Seagen Inc., a company with a strong oncology focus. The deal is anticipated to close either later this year or next, indicating Pfizer’s commitment to expanding its presence in the oncology sector and reinforcing its R&D capabilities in this critical area.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry